GNUBIOTICS
Gnubiotics Sciences SA (Gnubiotics), announced today a strategic partnership agreement with ADM, a global leader in human and animal nutrition. The strategic partnership is centered on the commercialization of innovative microbiome solutions for companion animal health and wellbeing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005749/en/
This strategic partnership provides ADM with unique access to cutting edge technologies and a pipeline of microbiome-focused innovation from Gnubiotics.
“We´re excited about this partnership with Gnubiotics, and the capabilities they bring, enabling pet parents to better understand their pets’ microbiome. With this knowledge, ADM can leverage its comprehensive pantry of pet and animal well-being solutions to improve individual pet health through precise nutrition and supplementation.” said Gustavo Zenaide, Vice President ADM Pet & Animal Well-being.
The gut microbiome is essential to the health and well-being of companion animals. Study data from Gnubiotics show Animal Milk Oligosaccharides (A.M.O.s) manufactured by Gnubiotics helped protect the microbiome of dogs from the negative effects of antibiotics. In 2021, Gnubiotics also announced patents covering microbiome-based markers to predict, diagnose and treat feline obesity, a major cause of diabetes and chronic kidney disease (CKD) in felines.
“We are pleased to work with ADM, a global leader in human and animal health and nutrition,” said Yemi Adesokan, CEO and Co-Founder, Gnubiotics. “We have developed products which have functional and clinically demonstrated applications for animal health and well-being. This strategic partnership with ADM is a major accomplishment for Gnubiotics as it represents validation of our science and technology. We are excited to collaborate with ADM to continue to develop and bring to market, data-driven microbiome-targeted solutions.”
About Gnubiotics
Gnubiotics is a Swiss biotech company pioneering the use of glycopeptides as immunomodulatory agents with resulting effects on microbiome and overall health. Our pipeline of microbiome targeted solutions includes GNUBIOME FI, a line of functional ingredients, and AMOBIOME Forte a supplement line designed for immunomodulation, microbiome modulation and microbiome recovery post antibiotic use in companion animals. Beyond its glycopeptide pipeline, Gnubiotics has also developed microbiome biomarkers which offers a view on microbiome health as well as predispositions, onset and progression of microbiome correlated diseases.
About ADM
ADM unlocks the power of nature to enrich the quality of life. We’re a premier global human and animal nutrition company, delivering solutions today with an eye to the future. We’re blazing new trails in health and well-being as our scientists develop groundbreaking products to support healthier living. We’re a cutting-edge innovator leading the way to a new future of plant-based consumer and industrial solutions to replace petroleum-based products. We’re an unmatched agricultural supply chain manager and processor, providing food security by connecting local needs with global capabilities. And we’re a leader in sustainability, scaling across entire value chains to help decarbonize our industry and safeguard our planet. From the seed of the idea to the outcome of the solution, we give customers an edge in solving the nutritional and sustainability challenges of today and tomorrow. Learn more at www.adm.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005749/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Euromonitor International unveils Global Consumer Trends for 20265.11.2025 14:00:00 CET | Press release
Consumers seek holistic wellbeing in the face of global challenges Authenticity and self-expression drive consumer behaviour and brand loyalty Wellness is going pro as consumers demand professional-grade solutions for everyday use Data analytics company Euromonitor International has today revealed its top Global Consumer Trends for 2026, with the annual report identifying four global trends that highlight crucial shifts in consumer behaviour. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105486775/en/ Euromonitor International Global Consumer Trends 2026 In a reality shaped by cost of living, authenticity and wellbeing expectations, these trends are at the core of consumer behaviour worldwide. Alison Angus, head of innovation at Euromonitor International, said: “The future of consumer behaviour is characterised by a desire for comfort, self-expression and cutting-edge wellness solutions, driven by the need for authentici
Merz Aesthetics®Announces New Arms and Abdomen* Indication for Ultherapy PRIME, the Only Ultrasound Solution With Integrated Real-Time Visualization5.11.2025 14:00:00 CET | Press release
Latest Intention for USE Expands to Improve the Appearance of Skin Laxity on the Posterior and Anterior Armsand Abdomen, to launch in the United States before worldwide expansion. Merz Aesthetics, the world’s largest dedicated medical aesthetics business, announced today the upcoming availability of UltherapyPRIMEto improve the appearance of skin laxity on the anterior arms and posterior arms, and abdomen. Ultherapy PRIME is the only solution with integrated real-time visualization to treat the upper face, lower face, neck, décolleté, and now the body*.1 The new indications will launch in the United States before expanding to markets worldwide, with commercial rollout in EMEA planned for early 2026.** We are excited to share updates with our customers soon and look forward to supporting practices and patients with these innovative solutions. “This indication expansion is proof of our incredible momentum, following last year’s successful Ultherapy PRIME launch,” said Bob Rhatigan, CEO,
Registrar Corp Acquires CMC Medical Devices to Make Global Compliance Quick and Easy5.11.2025 13:00:00 CET | Press release
Expands Registrar Corp’s reach to support over 75% of the global medical device market. Registrar Corp, a global leader in regulatory compliance and technology solutions and a Paine Schwartz Partners portfolio company, today announced the acquisition of CMC Medical Devices (CMC), a Spain-based provider of medical device regulatory, clinical, and compliance consulting services. The combination of Registrar Corp’s global network and CMC’s clinical and technical expertise creates a unified partner to help medical device and in vitro diagnostic (IVD) manufacturers bring products to market faster and with greater confidence. “We’re proud to welcome CMC Medical Devices to the Registrar Corp family,” said Raj Shah, CEO of Registrar Corp. “Together, we offer medical device manufacturers a single partner to navigate complex regulations and access the U.S., EU, and other key global markets—so they can focus on innovation rather than compliance.” “Joining Registrar Corp enables us to deliver even
Cybersecurity Leader Armis Closes $435 Million Round at $6.1 Billion Valuation5.11.2025 13:00:00 CET | Press release
In a pre-IPO round led by Growth Equity at Goldman Sachs Alternatives and with significant participation from CapitalG, Armis accelerates on the path to $1 billion in ARR and a public offering Armis, the cyber exposure management and security company, today announced a pre-IPO funding round of $435 million, bringing the company’s valuation to $6.1 billion. The round was led by Growth Equity at Goldman Sachs Alternatives with major participation from CapitalG, and was joined by new investor Evolution Equity Partners, alongside several existing investors. The investment round comes amid continued growth, with the company recently surpassing $300 million in Annual Recurring Revenue (ARR), growing over 50%. Armis has worked with over 40% of the Fortune 100, including 7 of the Fortune 10, and helps protect leading organizations around the globe, including manufacturers, airlines, financial services firms, healthcare institutions, and state and federal agencies. Yevgeny Dibrov, CEO and Co-Fo
Macrobond Selected by T. Rowe Price to Support Evolving Research and Investment Workflows5.11.2025 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, has been selected by T. Rowe Price to support the continued evolution of its cross-asset research and systematic strategy workflows. As financial institutions look to strengthen data-driven decision-making, the need for scalable technology and integrated platforms has never been more critical. T. Rowe Price’s decision to implement Macrobond reflects a broader commitment to enhancing research workflows with modern, flexible solutions built for the pace and complexity of today’s investment landscape. Meeting the Demands of a Dynamic Environment The ability to integrate complex data sets, streamline analysis, and support automation were key factors in the selection process. Macrobond’s API and flexible data infrastructure provided a strong foundation for collaboration. “T. Rowe Price is continually investing in technology to improve the efficiency and quality of our research processes,” said Tae Kim, Head of Fixed Income
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom